Leerink analyst Puneet Souda raised his price target for Myriad Genetics to $49 from $35 to reflect its 10-K filing detailing the quarterly changes to 2017 and 2018 revenue numbers, and the company’s updated full year FY19 and Q1 guidance. The analyst reiterates a Market Perform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.